Primary testicular diffuse large B-cell lymphoma shows an activated B-cell-like phenotype

Li, Dan; Xie, Peng; Mi, Can

doi:10.1016/j.prp.2010.04.005

Cited by 27 publications

(25 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4,36,[48][49][50] The variation in frequency is dependent on both the proportion of patients with advanced-stage disease (in which it is difficult to distinguish PTL from nodal DLBCL with testicular metastases) and the IHC algorithm used. 47 The true proportion of cases that are ABC type is likely to be at the higher end of the published estimates, because even though 6% to 36% of cases are CD10 1 in published series 36,48,50 and are classified as germinal center B-cell-like by the Hans algorithm, 47 many also express the B-cell activation marker MUM1.…”

Section: Cell-of-origin Studies and Chromosomal Translocationsmentioning

confidence: 99%

Primary testicular lymphoma

Cheah

Wirth

Seymour

2014

Blood

182

174

View full text Add to dashboard Cite

Primary testicular lymphoma (PTL) is a rare, clinically aggressive form of extranodal lymphoma. The vast majority of cases are histologically diffuse large B-cell lymphoma, but rarer subtypes are clinically important and must be recognized. In this review, we discuss the incidence, clinical presentation, and prognostic factors of PTL and present a summary of the recent advances in our understanding of its pathophysiology, which may account for the characteristic clinical features. Although outcomes for patients with PTL have historically been poor, significant gains have been made with the successive addition of radiotherapy (RT), full-course anthracycline-based chemotherapy, rituximab and central nervous system–directed prophylaxis. We describe the larger retrospective series and prospective clinical trials and critically examine the role of RT. Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone given every 21 days with intrathecal methotrexate and locoregional RT is the current international standard of care, a substantial minority of patients progress, representing an unmet medical need. Finally, we discuss new treatment approaches and recent discoveries that may translate into improved outcomes for patients with PTL.

show abstract

Section: Cell-of-origin Studies and Chromosomal Translocationsmentioning

confidence: 99%

Primary testicular lymphoma

Cheah

Wirth

Seymour

2014

Blood

182

174

View full text Add to dashboard Cite

show abstract

“…Al-Abbadi et al (13) studied 18 cases of testicular DLBCL and found that 89% of them belonged to the non-GCB subtype and all exhibited high proliferative activity. Furthermore, Li et al (14) also showed that 16 out of 17 testicular DLBCL cases belonged to the ABC subtype. However, two other studies have shown contrasting results.…”

Section: Discussionmentioning

confidence: 98%

Primary testicular lymphoma with subcutaneous masses as the sole manifestation of the first relapse and central nervous system lymphoma as the second relapse: A case report and literature review

Wang

Zhu

et al. 2014

Oncology Letters

View full text Add to dashboard Cite

Primary testicular lymphoma (PTL) accounts for ~1% of all non-Hodgkin’s lymphomas and has a marked tendency for systemic relapse. The current study presents a unique case of testicular diffuse large B-cell lymphoma of non-germinal center B-cell subtype, with subcutaneous masses as the sole manifestation of the first relapse and central nervous system lymphoma as the second relapse. Subcutaneous relapse and subsequent brain relapse are extremely rare signs of PTL dissemination. The patient received methotrexate-based combined chemotherapy and achieved a partial response. This case presents a rare pattern of treatment failure in this malignant clinical entity.

show abstract

“…Aquellos linfomas con expresión de CD10 y/o bcl-6 y carencia de MUM-1 pertenecen al subgrupo con fenotipo centrogerminal-like (CG) y tienen una mejor tasa de supervivencia y aquellos con negatividad para CD10 y positividad para MUM-1 pertenecen al subgrupo no-CG, también llamado Activado y tienen una peor tasa de supervivencia. Respecto a la localización testicular, hay estudios que demuestran una mayor tendencia a pertenecer al subgrupo no-CG (89%), como así ocurre en los casos aquí presentados, pudiendo ser esta, junto a la situación inmunoprivilegiada del testículo, una de las causas responsables de las bajas tasas de supervivencia de estos tumores 11,12 .…”

Section: Discussionunclassified